Company Profile

Avexegen Therapeutics Inc
Profile last edited on: 12/5/2017      CAGE: 7F8R1      UEI: ZNNEJRN8M415

Business Identifier: Novel first-in-class therapies for GI disorders
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

10210 Campus Point Drive Suite 150
San Diego, CA 92121
   (818) 288-6200
Location: Single
Congr. District: 50
County: San Diego

Public Profile

Avexegen Therapeutics is organized around working on novel breakthrough therapies for diseases with unmet needs beginning with the firm's first-in-class drug candidate, neuregulin-4, targeting treatment of GI disorders including Crohn's, ulcerative colitis and necrotizing enterocolitis, the latter a rare disease which afflicts premature infants. The firm's lead compound, Neuregulin-4, has been developed in collaboration with Children's Hospital Los Angeles.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
Less than .5M
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2022 2 NIH $3,167,139
Project Title: Neuregulin-4: a Novel Therapy for Inflammatory Bowel Disease

Key People / Management

  Arartin Asadourian -- President & CEO

  Soumitra Ghosh

  David Litzinger -- Cmc & Pharmaceutical Sciences Lead

  David Maggs -- Medical Lead & Co-Founder